JAN 20, 2021 7:49 PM PST

Designer Cytokine: Potential Therapeutic Approach for Paralysis

WRITTEN BY: Nouran Amin

Paralysis due to spinal cord damage remains an irreparable condition. However, a new therapeutic approach may bring renewed hope for paralysis patients. The approach involves a ‘designer’ cytokine that stimulates the nerve cells to regenerate. The cytokine is called hyper-interleukin-6.

"This is a so-called designer cytokine, which means it doesn't occur like this in nature and has to be produced using genetic engineering," explains Dietmar Fischer.

"Thus, gene therapy treatment of only a few nerve cells stimulated the axonal regeneration of various nerve cells in the brain and several motor tracts in the spinal cord simultaneously," points out Dietmar Fischer. "Ultimately, this enabled the previously paralyzed animals that received this treatment to start walking after two to three weeks. This came as a great surprise to us at the beginning, as it had never been shown to be possible before after full paraplegia."

Learn more about spinal trauma:

"This aspect would be particularly relevant for application in humans," stresses Fischer. "We are now breaking new scientific ground. These further experiments will show, among other things, whether it will be possible to transfer these new approaches to humans in the future."

Source: Science Daily  

About the Author
BS/MS
Nouran is a scientist, educator, and life-long learner with a passion for making science more communicable. When not busy in the lab isolating blood macrophages, she enjoys writing on various STEM topics.
You May Also Like
APR 28, 2022
Health & Medicine
Antidepressants Not Associated Improved Quality of Life
APR 28, 2022
Antidepressants Not Associated Improved Quality of Life
According to a recently published study in PLoS, antidepressants do not improve health-related quality of life (HRQoL) o ...
MAY 09, 2022
Cancer
A Gel Implant Protects from Cancer Recurrence
MAY 09, 2022
A Gel Implant Protects from Cancer Recurrence
Following a successful course of cancer treatment, a patient may enter remission. Remission, classified as either partia ...
MAY 20, 2022
Drug Discovery & Development
Drug Shows Promise in treating Spinal Cord Injury
MAY 20, 2022
Drug Shows Promise in treating Spinal Cord Injury
A drug developed by AstraZeneca preserves 80% of nerve function following spinal cord compression injury. The correspond ...
JUN 21, 2022
Cell & Molecular Biology
From sample collection straight to RT-qPCR
JUN 21, 2022
From sample collection straight to RT-qPCR
Skip the nucleic acid purification step in your cancer detection workflow. Learn more about how Thermo Fisher Scientific ...
JUN 04, 2022
Drug Discovery & Development
3g of Omega-3 Fatty Acids Daily May Lower Blood Pressure
JUN 04, 2022
3g of Omega-3 Fatty Acids Daily May Lower Blood Pressure
Around 3g of omega-3 fatty acids taken on a daily basis may be the optimal dose for lowering blood pressure. The corresp ...
JUN 26, 2022
Drug Discovery & Development
Acupuncture Alleviates Chronic Tension Headaches in Randomized Controlled Trial
JUN 26, 2022
Acupuncture Alleviates Chronic Tension Headaches in Randomized Controlled Trial
Results from a randomized controlled trial suggest that acupuncture may relieve symptoms of chronic tension-type headach ...
Loading Comments...